Intensity Therapeutics, Inc. INTS PHARMA
Company Overview
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -43.59% |
| 6 Months: | -47.36% |
| 3 Months: | +8.20% |
| 1 Month: | -1.68% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)43.34 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 87.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | INTS Intensity Therapeutics, Inc. PHARMA | 4.09 | -2.04 | $13.35M | 0.00% | -100.14% | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -1.93M | -1.77M | -1.25M | -1.22M | -2.49M | -4.74M | -5.07M | -3.57M | -3.39M | -2.71M | -2.73M | -2.53M |
| Net Income | -1.93M | -1.77M | -1.34M | -3.70M | -2.33M | -4.60M | -4.97M | -3.51M | -3.35M | -2.54M | -2.67M | -2.43M |
| Diluted EPS | -0.57 | -0.52 | -0.39 | -1.43 | -0.17 | -0.34 | -0.36 | -0.25 | -5.51 | -0.13 | -0.06 | -0.96 |
| R&D Expense | 1.39M | 1.16M | 774.00K | 859.00K | 1.35M | 2.81M | 3.56M | 2.15M | 2.19M | 1.54M | 1.55M | 1.20M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Income | -7.55M | -8.32M | -16.59M | -11.97M |
| Net Income | -7.58M | -10.54M | -16.27M | -11.61M |
| Diluted EPS | -2.22 | -1.38 | -29.24 | -8.56 |
| R&D Expense | 5.13M | 4.79M | 10.50M | 6.79M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 1.76M | 17.30M | 4.78M | 14.10M |
| Total Equity | -8.69M | -15.10M | 13.16M | 2.92M | 11.88M |
| Cash & Equivalents | - | 1.31M | 8.56M | 2.59M | 11.92M |
| Total Liabilities | - | 6.86M | 4.13M | 1.86M | 2.23M |
| Current Liabilities | - | 6.82M | 3.96M | 1.75M | 2.15M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -5.48M | -7.21M | -15.22M | -9.23M |
| Investing Cash Flow | 0 | -6.02M | 6.35M | 0 |
| Financing Cash Flow | 2.25M | 20.47M | 2.90M | 18.56M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | 50.2% | -80.1% | -557.5% | -97.7% |
| ROCE % | 149.2% | -62.4% | -547.7% | -100.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Kmt Wealth Management, LLC | 15.21% | 496.49K | $2.04M |
| 2 | Kingsbury Capital Investment Advisors LLC | 15.21% | 496.49K | $2.04M |
| 3 | Rothschild Wealth, LLC | 0.82% | 26.72K | $109.83K |
| 4 | Vanguard Capital Management LLC | 0.81% | 26.57K | $109.20K |
| 5 | Sapient Capital LLC | 0.80% | 26.01K | $106.88K |
| 6 | Nano Cap New Millennium Growth Fund L P | 0.77% | 25.00K | $102.75K |
| 7 | Geode Capital Management, LLC | 0.70% | 22.79K | $93.65K |
| 8 | FNY Investment Advisers, LLC | 0.67% | 22.00K | $90.42K |
| 9 | Mesirow Financial Investment Management, Inc. | 0.43% | 14.12K | $58.02K |
| 10 | Vanguard Fiduciary Trust Co | 0.28% | 9.12K | $37.49K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for INTS
Why Did INTS Stock Plummet 25% Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNNjlGNWltUUNZSXdYOVctWGlYd1dHQWxoTVVnaDdPNTF1MDNFTXVDZWhHYXRRUjQxM3hUdnFGTVdSN0lhX2lvVzRxV1dYVWgwT0xBdEI0el9TYkVORmpNLVoxS09UcURYNDI1aVloUkZFX1E1b0VoS3Z0RXd4YmRzV3NhNEpJbjlrUVJhb2…
A cancer therapy developer will post a presentation online Sept. 11 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPeFRzNzY2UDZ3TEN1NllhWGFFOFJpYk5YT3dNWXc4Rl9GQmRvTkRjbFlmRXo5SFhoY1FvN2R3aTRrTFNzWGl1dVcxa3N1aWVMSnJFZjNZdHJaNFN5azBoQXpNdlc5OGI3ZzdSVW5iV0R6QWZJazNIZk1HOFl3YXpMakZYa3EtdHFFOFE4MF…
Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxNWFRzZU1BV2FpNlJ3ejBkOE1FT2tEbXB3WEhVLVVhWWpaSEFSYVozUHpTcWFyLXl6N25hNmVpMjhLWFBMcmtvcnBlM1VVcFBTOG1HdTZsY2R0ZThnOFpuQ01DcUhabWdfZDd1aUMzaE93SHpROG16RDR0Y2M4WWJVR3JBYXd0TmZHc3dyTX…
Dolphins camp: Malik Willis throws 2 INTs as offense struggles; plus stock up, stock down - Sun Sentinel
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxPY0tWV1VRWkZmcS1HbnZKUFBEU1dodE5CUndLMTVkU2hfT3dVM1hERjVlMFdtNEVieGc5WmRTOXk4UzhjZmJXSDhtanJGV2dxOTcxeklGVG5HTTByZlZwZ19TakQ3R2xxWGwyRUdJeUF4c1NheXl5X0Y0a2VTV2h2QVoxSXo4OVU3dER3U3…
INTS Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5EbzhVYzc0RW85ajZzWGRSb0dPa0ZYa293WTN1YS1vU3dwc0hGdS1OVm45SWRGWlhzZi1nSzcxZlEtRDV2SkpPaTVBTk1maG5jNURmUDZhMnIwOF9NSG1WZEl0TlZTTVkxcnQtcTFDQ2NJQ0ZrSV9Qam9B?oc=5" target="_blank">INT…
INTS - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBiTWxGY3dlOUI4VTVoWmFEcnlhdU9ab3U5R21tOTdrZUg5bUtocVFVdVpWTXZfUFE2SHpOMHA0SlhVeldwZlE?oc=5" target="_blank">INTS</a> <font color="#6f6f6f">Finviz</font>…
INTS — Frequently Asked Questions
What is the current share price of Intensity Therapeutics, Inc. (INTS)?
As of 2026-09-19 21:16 PDT, Intensity Therapeutics, Inc. (INTS) trades at $4.09 on NasdaqCM. Its 52-week range is $3.62 to $33.00.
What is the market capitalisation of INTS?
Intensity Therapeutics, Inc. (INTS) has a market capitalisation of $13.35M on NasdaqCM.
What is the P/E ratio of INTS?
INTS trades at a trailing price-to-earnings (P/E) ratio of -2.04. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.31.
Is INTS a good stock to buy?
This page provides a data-driven analysis of Intensity Therapeutics, Inc. (INTS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.